Crinetics Pharmaceuticals, Inc. financial data

Symbol
CRNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
10222 Barnes Canyon Road, Bldg. #2, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.84K % +51.9%
Debt-to-equity 10.9 % -32.6%
Return On Equity -30.9 % +41.6%
Return On Assets -27.9 % +38.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 93M shares +18%
Common Stock, Shares, Outstanding 92.9M shares +36.3%
Entity Public Float 3.5B USD +250%
Weighted Average Number of Shares Outstanding, Basic 80.8M shares +39.1%
Weighted Average Number of Shares Outstanding, Diluted 80.8M shares +39.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 240M USD +42.5%
General and Administrative Expense 99.7M USD +71.7%
Operating Income (Loss) -339M USD -52.2%
Nonoperating Income (Expense) 40.9M USD +208%
Net Income (Loss) Attributable to Parent -298M USD -39.1%
Earnings Per Share, Basic -3.69 USD/shares 0%
Earnings Per Share, Diluted -3.69 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 265M USD +382%
Cash, Cash Equivalents, and Short-term Investments 1.4B USD +151%
Other Assets, Current 1.21M USD +169%
Assets, Current 1.38B USD +140%
Property, Plant and Equipment, Net 12.1M USD +10.9%
Operating Lease, Right-of-Use Asset 43.5M USD -6.54%
Other Assets, Noncurrent 2.83M USD +41.5%
Assets 1.43B USD +126%
Accounts Payable, Current 5.85M USD -10.6%
Liabilities, Current 59.7M USD +35.8%
Operating Lease, Liability, Noncurrent 44.6M USD -6.28%
Other Liabilities, Noncurrent 829K USD
Liabilities 110M USD +14.1%
Common Stocks, Including Additional Paid in Capital 2.28B USD +91%
Accumulated Other Comprehensive Income (Loss), Net of Tax 963K USD -1.43%
Retained Earnings (Accumulated Deficit) -952M USD -45.6%
Stockholders' Equity Attributable to Parent 1.32B USD +146%
Liabilities and Equity 1.43B USD +126%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 92.9M shares +36.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 266M USD +373%
Deferred Tax Assets, Valuation Allowance 282M USD +52.4%
Deferred Tax Assets, Gross 292M USD +49.8%
Operating Lease, Liability 51.7M USD -0.01%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -298M USD -42.4%
Lessee, Operating Lease, Liability, to be Paid 79.4M USD -5.35%
Property, Plant and Equipment, Gross 19.8M USD +24.1%
Operating Lease, Liability, Current 7.15M USD +71.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.8M USD -9.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.47M USD +66.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 27.7M USD -13.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7M USD +3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 10.7M USD +53.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.21M USD +3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 69.4M USD +69.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%